Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB07133 in Unresectable HCC
NCT06141096Phase 2Recruiting
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Jun 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mbo7133 in hepatocellular carcinoma (HCC) (3 arms), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoint: Progression-Free Survival. Started Jan 2020; status: recruiting.
02
Drugs
mbo7133
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06141096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141096.